Investor Presentaiton

Q2 2023 EMGALITY SALES INCREASED 8% Millions U.S. sales increased 9% International sales increased 3% $169 $169 $149 $154 $157 Q1 Q2 Not for promotional use 2022 2023 $176 13 WK RA TRX SOM U.S. TRX SOM and Market Volume 44% 42% 40% 38% Emgality 80 76 Market 2 72 Lilly 64 68 88 13 WK RA TRx Market Volume (000s) | 36% 60 Q3 Q4 Jun Sep Dec Mar Jun Sep Dec Mar Jun 2021 2021 2021 2022 2022 2022 2022 2023 2023 Source: IQVIA NPA TRX 3MMA, weekly data June 30, 2023; RA = rolling average TRx data is representative of the injectable CGRP market 2023 Q2 EARNINGS 36

View entire presentation